Nanosynthetic Graft Technology

Our ultimate goal is 100% fusion

 

 

Our vision is clinical success for all patients

09_11_18_Sirakoss-28.jpg

Rooted in a profound understanding of the clinical needs, market challenges and the technical opportunities in synthetic bone grafting, SIRAKOSS has used its  robust scientific foundation to achieve approval for a first product that gives us a launchpad to execute the core objective for which the company was conceived – the development of  clinical data  that justifies widespread adoption of its technology by evidencing clinical efficacy coupled with minimal risk.

SIRAKOSS will transform patient outcomes by providing surgeons with evidence based nanosynthetic bone regeneration solutions to become the leader in bone repair.


News

31 January 2019

Today, SIRAKOSS announced receipt of CE Mark for Osteo3, our nanosynthetic bonegraft substitute designed to improve patient healing and to be completely reabsorbed into bone.


Management Team

09_11_18_Sirakoss-1.jpg

Dr Tom Buckland

Tom trained as a Mechanical Engineer, but rapidly appreciated the limitations of current medical device technologies compared to biological and physiological systems. Deep sector expertise in orthobiologic technologies and markets as well as having held senior commercial, operational and product development positions in successful start-ups and larger organisations. Passionate about improving clinical outcomes in Medical Devices, he believes the Osteo3 technology represents a truly unique opportunity in bone grafting.

09_11_18_Sirakoss-32.jpg

Prof Iain Gibson

Iain holds the position of Professor in Acellular Regenerative Medicine at the University of Aberdeen. His research is focussed on developing innovative orthobiologic technologies and he has a strong record of successful R&D and technology transfer. He is an inventor of 10 patent families and he has published extensively in this field. In 2011, he founded SIRAKOSS to translate the transformative Osteo3 technology from academic discovery through to clinical use.

09_11_18_Sirakoss-35.jpg

Dr Jordan Conway

Jordan is a co-inventor of the Osteo3 technology. Having co-founded SIRAKOSS in 2011, he has since played a pivotal role developing, translating and advancing the technology into new formulations. Prior to SIRAKOSS, he worked for the University of Aberdeen under a Proof of Concept award to establish the initial technology behind the company. He holds a PhD in chemistry which was funded by a Royal Commission for the Exhibition of 1851 Industrial Fellowship award.


Board of Directors

Dr Tom Buckland

Prof Iain Gibson

Ms Kyparissia Sirinakis

Mr Sinclair Dunlop